Stock listing
Stockholm:FLUO FluoGuide A/S Aktie
Home listing (Stockholm) of FluoGuide A/S
Follow FluoGuide A/S into a list and get an email when it puts out news.
Share price · OMXSTO:FLUO
29.50 SEK -2.10 (-6.6%)
Close on Nov 20, 2026
- Day range
- 29.00 – 29.90 SEKNov 20, 2026
- Volume
- 7,913 sharesNov 20, 2026
- Market cap
- 482.3M SEKAt the close on Nov 20, 2026 · price × 16.35M shares outstanding
- 52-week range
- 28.00 – 47.80 SEKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 165,314 SEKMedian day 4,274 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:FLUO · Home | 29.50 SEK | -2.10 (-6.6%) | 7,913 | 29.60 | 29.90 | 29.00 | 31.60 | Close on Nov 20, 2026 |
| Frankfurt:96X | €2.45 EUR | -0.08 (-3.2%) | — | €2.47 | €2.48 | €2.45 | €2.53 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXSTO:FLUO · SEK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 29.50 | -2.10 | -6.6% | 29.60 | 29.90 | 29.00 | 7,913 | |
| 31.60 | +3.50 | +12.5% | 28.60 | 33.50 | 28.60 | 8,904 | |
| 28.10 | -1.70 | -5.7% | 29.80 | 30.20 | 28.10 | 8,483 | |
| 29.80 | +0.50 | +1.7% | 28.10 | 34.00 | 28.10 | 5,213 | |
| 29.30 | +0.10 | +0.3% | 29.80 | 29.80 | 29.10 | 3,677 | |
| 29.20 | +0.30 | +1.0% | 29.40 | 29.40 | 28.00 | 6,636 | |
| 28.90 | -1.50 | -4.9% | 29.20 | 29.80 | 28.90 | 1,868 | |
| 30.40 | +0.80 | +2.7% | 29.60 | 30.70 | 29.40 | 2,023 | |
| 29.60 | -0.50 | -1.7% | 30.90 | 30.90 | 29.60 | 5,648 | |
| 30.10 | -0.20 | -0.7% | 30.70 | 31.40 | 30.10 | 2,890 | |
| 30.30 | -0.20 | -0.7% | 29.40 | 30.30 | 29.40 | 4,744 | |
| 30.50 | 0.00 | 0.0% | 30.60 | 31.30 | 30.50 | 1,594 | |
| 30.50 | -1.00 | -3.2% | 31.50 | 31.50 | 30.00 | 2,542 | |
| 31.50 | +0.90 | +2.9% | 29.40 | 31.50 | 29.40 | 2,809 | |
| 30.60 | -0.40 | -1.3% | 31.20 | 31.30 | 30.00 | 5,659 | |
| 31.00 | +1.00 | +3.3% | 29.70 | 31.60 | 29.70 | 6,993 | |
| 30.00 | -1.50 | -4.8% | 30.10 | 30.50 | 29.10 | 6,307 | |
| 31.50 | +0.60 | +1.9% | 30.50 | 31.50 | 30.50 | 993 | |
| 30.90 | -0.70 | -2.2% | 30.20 | 33.10 | 30.10 | 13,074 | |
| 31.60 | +1.50 | +5.0% | 29.40 | 31.60 | 28.10 | 14,018 | |
| 30.10 | 0.00 | 0.0% | 29.50 | 30.50 | 28.90 | 13,452 | |
| 30.10 | -0.50 | -1.6% | 30.20 | 30.20 | 29.20 | 4,546 | |
| 30.60 | -0.30 | -1.0% | 29.70 | 30.80 | 29.70 | 1,522 | |
| 30.90 | +0.50 | +1.6% | 30.80 | 31.50 | 30.00 | 8,604 | |
| 30.40 | -1.30 | -4.1% | 33.00 | 33.00 | 30.30 | 9,460 | |
| 31.70 | +0.30 | +1.0% | 31.40 | 31.80 | 30.80 | 3,407 | |
| 31.40 | -0.30 | -0.9% | 31.70 | 32.30 | 29.10 | 12,069 | |
| 31.70 | -1.30 | -3.9% | 35.30 | 35.30 | 31.00 | 12,093 | |
| 33.00 | -0.90 | -2.7% | 33.90 | 33.90 | 31.80 | 1,469 | |
| 33.90 | +0.10 | +0.3% | 33.70 | 35.40 | 31.90 | 7,480 | |
| 33.80 | +0.10 | +0.3% | 33.70 | 36.90 | 31.70 | 8,711 | |
| 33.70 | -1.30 | -3.7% | 33.60 | 35.00 | 33.00 | 5,405 | |
| 35.00 | +1.10 | +3.2% | 32.60 | 35.00 | 32.60 | 3,236 | |
| 33.90 | +0.10 | +0.3% | 33.10 | 33.90 | 32.50 | 4,002 | |
| 33.80 | -1.60 | -4.5% | 34.00 | 34.90 | 33.50 | 2,980 | |
| 35.40 | +1.80 | +5.4% | 35.80 | 35.80 | 32.50 | 10,391 | |
| 33.60 | -1.50 | -4.3% | 35.20 | 35.90 | 32.90 | 5,671 | |
| 35.10 | +0.10 | +0.3% | 32.00 | 36.80 | 32.00 | 2,509 | |
| 35.00 | +1.40 | +4.2% | 32.00 | 35.00 | 32.00 | 3,179 | |
| 33.60 | +0.60 | +1.8% | 32.90 | 33.90 | 32.90 | 5,803 | |
| 33.00 | -1.50 | -4.3% | 33.10 | 33.80 | 32.50 | 2,147 | |
| 34.50 | -0.50 | -1.4% | 34.20 | 34.50 | 32.40 | 2,991 | |
| 35.00 | +1.60 | +4.8% | 33.70 | 36.70 | 33.70 | 6,491 | |
| 33.40 | +0.40 | +1.2% | 33.00 | 33.40 | 33.00 | 1,898 | |
| 33.00 | -0.20 | -0.6% | 33.40 | 33.40 | 32.20 | 1,816 | |
| 33.20 | -0.50 | -1.5% | 33.30 | 33.60 | 32.50 | 3,936 | |
| 33.70 | -1.50 | -4.3% | 35.10 | 35.20 | 33.10 | 1,067 | |
| 35.20 | -1.00 | -2.8% | 34.50 | 35.30 | 33.30 | 4,786 | |
| 36.20 | +1.40 | +4.0% | 34.10 | 36.20 | 34.10 | 1,083 | |
| 34.80 | -0.90 | -2.5% | 35.90 | 35.90 | 34.50 | 5,774 | |
| 35.70 | 0.00 | 0.0% | 34.10 | 36.90 | 34.10 | 3,852 | |
| 35.70 | -0.40 | -1.1% | 34.00 | 35.70 | 34.00 | 2,804 | |
| 36.10 | 0.00 | 0.0% | 36.10 | 36.10 | 35.00 | 1,022 | |
| 36.10 | -1.40 | -3.7% | 35.10 | 37.50 | 35.10 | 2,195 | |
| 37.50 | +2.00 | +5.6% | 35.50 | 37.90 | 34.30 | 3,393 | |
| 35.50 | +1.40 | +4.1% | 33.90 | 35.50 | 33.60 | 5,086 | |
| 34.10 | 0.00 | 0.0% | 33.70 | 34.50 | 33.60 | 3,237 | |
| 34.10 | +0.60 | +1.8% | 33.20 | 35.20 | 33.10 | 7,245 | |
| 33.50 | +2.50 | +8.1% | 33.80 | 33.80 | 32.00 | 3,576 | |
| 31.00 | -2.40 | -7.2% | 31.10 | 33.30 | 31.00 | 9,711 | |
| 33.40 | +2.30 | +7.4% | 30.80 | 33.40 | 30.80 | 7,307 | |
| 31.10 | -0.60 | -1.9% | 31.00 | 33.20 | 30.50 | 6,849 | |
| 31.70 | -0.50 | -1.6% | 32.30 | 32.80 | 31.70 | 2,151 | |
| 32.20 | -0.60 | -1.8% | 32.20 | 32.20 | 31.60 | 830 |
- Ticker
- Stockholm:FLUO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stockholm
- Currency
- SEK
What changed lately
Latest news release · Oct 5, 2026
FluoGuide Enrolls First Patient in U.S. Phase 2 Trial of FG001 in High-Grade Glioma
Latest deck · Jan 21, 2026
Investor Presentation (January 2026)
Investor deck · 11 slides
Latest news
FluoGuide Enrolls First Patient in U.S. Phase 2 Trial of FG001 in High-Grade Glioma
Oct 5, 2026
Closed 33.70 (-3.7%) on Oct 5, 2026
FluoGuide Enters Collaboration with Leica Microsystems, a World Leading Medical Technology Company
Oct 2, 2026
Closed 33.70 (-3.7%) on Oct 5, 2026
FluoGuide A/S publishes interim report for Q2 2026
Aug 25, 2026
Closed 33.40 (+7.4%) on Aug 25, 2026
Invitation to FluoGuide A/S live webcast on 25 August 2026
Aug 12, 2026
Closed 32.00 (+3.6%) on Aug 12, 2026
FluoGuide A/S publishes interim report for Q1 2026
May 27, 2026
Closed 39.80 (-5.7%) on May 27, 2026
Invitation to FluoGuide A/S live webcast on 27 May 2026
May 13, 2026
Closed 42.10 (-0.7%) on May 13, 2026
FluoGuide Receives FDA Fast Track Designation for FG001 in High-Grade Glioma
Mar 18, 2026
Closed 37.60 (+9.0%) on Mar 19, 2026
Notice of Annual General Meeting in FluoGuide A/S
Mar 10, 2026
Closed 31.70 (-3.4%) on Mar 11, 2026
FluoGuide A/S Publishes Annual Report For The Fiscal Year 2025
Feb 25, 2026
Closed 35.50 (0.0%) on Feb 25, 2026
FluoGuide A/S Publishes Interim Report For Q4 2025
Feb 25, 2026
Closed 35.50 (0.0%) on Feb 25, 2026
FluoGuide A/S on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 17 in the last 12 months · 28 in all · newest Oct 5, 2026 · oldest 2025
- Decks
- 5 decks · latest Jan 21, 2026
Where FluoGuide A/S is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:FLUO · Home listing · This page | Stockholm | Sweden | SEK |
| Frankfurt:96X | Frankfurt | Germany | EUR |
Valuation
EV/sales 5,549× against a median of 5.9×: the highest of 6 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 448.8M SEK
- P/E
- Loss
- EV/sales
- 5,549×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 10.5×
- Gross margin
- −772.1%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.9×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| FluoGuide A/S · OMXSTO:FLUO | US$47.30M | US$44.02M | n/a | 5,549× | n/a | 10.5× | n/a | 0.9× | n/a |
| SYNTHAVERSE Spolka Akcyjna · GPW:SVE | US$48.67M | US$70.97M | n/a | 5.9× | n/a | 1.7× | −43.1% | 0.8× | n/a |
| Heron Therapeutics, Inc. · NASDAQ:HRTX | US$48.04M | US$156.3M | n/a | 1.1× | n/a | 9.8× | −14.5% | 26.8× | 1.93 |
| Helix BioPharma Corp. · TSX:HBP | US$47.94M | US$50.27M | n/a | n/a | n/a | 4.8× | n/a | 0.3× | 0.36 |
| Oncolytics Biotech Inc. · NASDAQ:ONCY | US$47.66M | US$45.23M | n/a | n/a | n/a | n/a | n/a | n/a | 1.27 |
| THX Pharma · EURONEXT:ALTHX | US$47.23M | US$30.92M | n/a | n/a | n/a | 14.5× | n/a | 0.9× | n/a |
| Rafael Holdings, Inc. · NYSE:RFL | US$47.10M | US$25.00M | n/a | 28.6× | n/a | 0.7× | n/a | 0.0× | 0.92 |
| Bio-fd&c Co. Ltd · KRX:251120 | US$46.46M | US$5.26M | 9.8× | 0.4× | 0.9× | 0.9× | 32.8% | 0.0× | n/a |
| Andros Pharmaceuticals Co., Ltd. · TPEX:6917 | US$46.01M | US$35.88M | n/a | 213× | n/a | 3.1× | −969.3% | 0.0× | n/a |
| Werewolf Therapeutics, Inc. · NASDAQ:HOWL | US$46.01M | US$4.14M | n/a | n/a | n/a | 6.8× | n/a | 0.0× | 1.55 |
| MegaPro Biomedical Co., Ltd. · TPEX:6827 | US$45.95M | US$43.30M | n/a | n/a | n/a | 7.0× | n/a | 0.0× | n/a |
| Median of the others | US$47.16M | US$39.59M | 9.8× | 5.9× | 0.9× | 4.8× | −28.8% | 0.0× | 1.27 |
Forecasts
Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 54.11 SEK · Analysts' mean
- EPS, year to Dec 2026
- -3.93 · 1 analyst
- Revenue, year to Dec 2026
- 110K · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Morten Albrechtsen | Chief Executive Officer (CEO) |
| Ole Larsen | Chief Financial Officer (CFO) |
| Donna Haire | Chief Operating Officer |
| Andreas Kjaer | Chief Scientific Officer (CSO) |
Board
| Director | Role |
|---|---|
| Peter Mørch Eriksen | Chairman of the board |
| Andreas Kjaer | Chief Scientific Officer (CSO) |
| Camilla Harder Hartvig | Member of the board |
| Kim Domela Kjøller | Member of the board |
| Mats Thorèn | Vice chairman of the board |
| Michael Engsig | Member of the board |
Events
- Next results
- Nov 26, 2026 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Aug 25, 2026 · After close | −7.2% |
| Q1 2026 | May 27, 2026 · After close | +2.8% |
| Q4 2025 | Feb 25, 2026 · Before open | 0.0% |
| Q3 2025 | Nov 27, 2025 · Before open | −1.9% |
| Q2 2025 | Aug 28, 2025 · Before open | +3.8% |
| Q1 2025 | May 28, 2025 · Before open | −2.8% |
| Q4 2024 | Feb 27, 2025 · Before open | −4.4% |
| Q3 2024 | Nov 27, 2024 · Before open | +2.9% |
| Q2 2024 | Aug 29, 2024 · Before open | −1.2% |
| Q1 2024 | May 30, 2024 · Before open | −1.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Feb 28, 2024 · Before open | −5.2% |
| Q3 2023 | Nov 29, 2023 · Before open | −3.8% |
| Q2 2023 | Aug 30, 2023 · Before open | +1.1% |
| Q1 2023 | May 31, 2023 · Before open | −1.4% |
| Q4 2022 | Feb 28, 2023 · Before open | +1.7% |
| Q3 2022 | Nov 24, 2022 · Before open | −0.5% |
| Q2 2022 | Aug 25, 2022 · Before open | −2.0% |
| Q1 2022 | May 31, 2022 · Before open | +0.6% |
| Q4 2021 | Mar 30, 2022 · Before open | +1.3% |
| Q3 2021 | Nov 15, 2021 · Before open | +0.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2026) | Investor deck | 11 slides | Jan 21, 2026 |
| Investor Presentation (January 2024) | Investor deck | 51 slides | January 2024 |
| Investor Presentation (February 2023) | Investor deck | 43 slides | February 2023 |
| Investor Presentation (November 2022) | Investor deck | 29 slides | November 2022 |
| IPO Roadshow (March 2019) | IPO roadshow | 20 slides | March 2019 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of shares Closed: SEK 104M raised · SEK 38 a share · Navia Corporate Finance AB +4 Dealers: Navia Corporate Finance AB (co-lead), Redeye AB (co-lead), Translution Capital (co-lead), Navia Corporate Finance (co-lead), Redeye (co-lead) Buyers: Several of the Company's major and institutional shareholders (expressed interest in participating with approximately SEK 95 million) Use of proceeds: Phase II trials of FG001 in HGG in the US and in head and neck cancer, CMC and drug manufacturing for phase III HGG trial, and general corporate purposes | Nov 3, 2025 | US$10.96M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in DKK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 385.0K | 423.0K | 6.51M | 9.61M | 0 | ||
| Cost of revenue | 571.2K | |||||||
| Gross profit | -571.2K | 385.0K | 423.0K | 6.51M | 9.61M | |||
| Research and development | 18.9M | |||||||
| Selling, general and administrative | 24.1M | 20.6M | 20.6M | 8.88M | ||||
| Operating income | -41.0M | -32.6M | -43.7M | -32.2M | -28.8M | -22.2M | -10.7M | -56.7K |
| Depreciation and amortization | 571.2K | 456.0K | 265.0K | 251.0K | 158.0K | 119.0K | 10.6M | 56.7K |
| EBITDA | -40.4M | -32.1M | -43.4M | -32.0M | -28.7M | -22.0M | -97.0K | 0 |
| Interest expense | 4.50M | 86.0K | 43.0K | 175.0K | 216.0K | 51.0K | 965.0K | 0 |
| Income before tax | -46.0M | -34.5M | -43.9M | -32.8M | -29.3M | -22.2M | -11.7M | -57.8K |
| Income tax | -5.63M | -5.50M | -5.50M | -5.50M | -5.50M | -4.73M | -2.05M | -1.09K |
| Net income | -40.4M | -29.0M | -38.4M | -27.3M | -23.8M | -17.5M | -9.65M | -57.8K |
| Earnings per share, basic | -2.87 | -2.23 | -3.22 | -2.33 | -2.15 | -1.78 | -1.49 | -0.09 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 48.8M | 18.6M | 21.7M | 26.0M | 46.8M | 10.6M | 2.34M | 59.0K |
| Short-term investments | 30.0M | 200 | ||||||
| Receivables | 5.93M | 446.0K | 915.0K | 3.36M | 566.0K | 554.0K | 2.38M | |
| Current assets | 86.8M | 26.5M | 28.3M | 34.9M | 52.8M | 16.1M | 4.85M | 75.0K |
| Property, plant and equipment | 53.0K | 211.0K | ||||||
| Total assets | 88.3M | 28.4M | 29.6M | 35.6M | 53.3M | 16.7M | 5.24M | 75.0K |
| Accounts payable | 2.68M | 2.38M | 4.09M | 1.60M | 6.83M | 2.69M | 489.0K | 13.0K |
| Current liabilities | 5.73M | 4.92M | 16.3M | 3.65M | 14.6M | 12.3M | 696.0K | 68.0K |
| Long-term debt | 27.6M | 0 | ||||||
| Total debt | 28.3M | 624.0K | 10.8M | 205.0K | 57.0K | 218.0K | ||
| Total liabilities | 33.8M | 5.31M | 16.9M | 3.65M | 14.6M | 12.3M | 696.0K | 68.0K |
| Shareholders' equity | 54.6M | 23.1M | 12.7M | 32.0M | 38.7M | 4.41M | 4.54M | 7.00K |
| Shares outstanding | 14.1M | 13.0M | 11.9M | 11.7M | 11.0M | 9.80M | 6.48M | 675.3K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -37.8M | -29.2M | -31.8M | -37.6M | -15.1M | -8.85M | -10.6M | -1.09K |
| Capital spending | 0 | -850.0K | 0 | -64.0K | 0 | 0 | -378.0K | 0 |
| Free cash flow | -37.8M | -30.0M | -31.8M | -37.7M | -15.1M | -8.85M | -10.9M | -1.09K |
| Cash from investing | -30.6M | -987.0K | -37.0K | -117.0K | -42.0K | -390.0K | -390.0K | |
| Cash from financing | 99.3M | 27.1M | 27.5M | 17.0M | 51.2M | 17.2M | 13.2M | 65.5K |
| Change in cash | 29.1M | -3.06M | -4.34M | -20.7M | 36.1M | 8.29M | 2.29M | 64.4K |
Cap table
Built by 6ix from FluoGuide A/S’ releases · as of Nov 3, 2025
- Common shares
- 16,349,313
- Fully diluted
- 16,349,313
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 16,349,313 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 16,349,313 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Andreas Kjaer | Chief Scientific Officer (CSO) · Since at least Nov 5, 2026 |
| Camilla Harder Hartvig | Member of the board · Since at least Mar 10, 2026 |
| Donna Haire | Chief Operating Officer · Since at least Mar 18, 2026 |
| Kim Domela Kjøller | Member of the board · Since at least Mar 10, 2026 |
| Mats Thorèn | Vice chairman of the board · Since at least Mar 10, 2026 |
| Michael Engsig | Member of the board · Since at least Mar 10, 2026 |
| Morten Albrechtsen | Chief Executive Officer (CEO) · Since at least Oct 5, 2026 |
| Ole Larsen | Chief Financial Officer (CFO) · Since at least Aug 25, 2026 |
| Peter Mørch Eriksen | Chairman of the board · Since at least Mar 10, 2026 |
Log in to ask 6ix AI your own questions about FluoGuide A/S.